Program
zanzalintinib
Also written as “Zanzalintinib” and “XL092”.
Its studies are mostly in Carcinoma, Renal Cell · Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Adenoma, Islet Cell, led by 3 companies.
Drug pageZanzalintinib: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Exelixisits history only | 1312 open or running | phase 3since Jun 16, 2022 | Feb 15, 2019 | Dec 15, 2026phase 3 · NCT05678673 |
| Merck | 33 open or running | phase 3since Nov 7, 2025 | Jun 25, 2025 | Nov 27, 2030phase 3 · NCT07489495 |
| Hoffmann-La Rocheits history only | 10 open or running | phase 2since Nov 7, 2017 | Nov 7, 2017 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb and Arcus Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 21, 2022Named zanzalintinibINNProposed as its International Nonproprietary Name in WHO's List 127 · before, XL092
- Jun 25, 2025First study: phase 2 study in Carcinoma, Renal CellFirst studyNCT07049926 · 140 planned · United States, Chile, France and more
- Nov 7, 2025Phase 3 study in Carcinoma, Renal CellNCT07227402 · 904 planned · United States, Argentina, Australia and more
- Mar 20, 2026Phase 3 study in Carcinoma, Renal CellNCT07489495 · 758 planned · United States, Argentina, Australia and more
Ahead
- Nov 27, 2030Primary completion: phase 3 study in Carcinoma, Renal CellNCT07489495
- Oct 26, 2031Primary completion: phase 2 study in Carcinoma, Renal CellNCT07049926
- Feb 27, 2032Primary completion: phase 3 study in Carcinoma, Renal CellNCT07227402
TargetBeta
“An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) hepatocyte growth factor receptor (c-Met; HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), AXL and MER, ”NCIt, by rule
Studies
All 3 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07489495Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Recruiting | Nov 27, 2030 | 758 |
| NCT07227402Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Recruiting | Feb 27, 2032 | 904 |
| NCT07049926Carcinoma, Renal Cell · United States, Chile, France and more | 2 | Recruiting | Oct 26, 2031 | 140 |
How it is read
Names in the registry
- “Zanzalintinib”, 12 entries
- “XL092”, 4 entries
- “zanzalintinib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 5 studies
- Neoplasms, 3 studies
- Colorectal Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Adenoma, Islet Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.